Endologix (NASDAQ: ELGX), a developer of medical devices for aortic disorders, brought in a new face for the VP of global marketing position.
Haemonetics
Vision-Sciences puts Cynthia Ansari in the corner office | Personnel Moves
Endoscopic device maker Vision-Sciences Inc. (NSDQ:VSCI) announced that they had found someone to take over the corner office, naming Cynthia Ansari CEO.
Ansari steps will take over the top seat from interim CEO Warren Bielke, who has steered the company since his appointment in November, 2009, after previous CEO Ron Hadani resigned for personal reasons.
Recall hurts Haemonetics in its first quarter 2012 | Earnings Roundup
Blood management solutions giant Haemonetics Corp.’s (NYSE:HAE) first quarter 2012 financials saw a slide in sales and revenue driven by the voluntary recall of its OrthoPAT autotransfusion device.
Analyst: $2 billion Immucor deal bodes well for Haemonetics
The $2 billion buyout of Immucor Inc. (NSDQ:BLUD) by a private equity firm could turn out to be a boost for Haemonetics Corp. (NYSE:HAE), according to analysts from Morgan Keegan.
In a note to investors, Keegan analysts reaffirmed the Braintree, Mass.-based blood management company’s “outperform” rating and set a $76 price rating on shares of HAE. The price target is a 14 percent premium over the company’s closing price of $66.58 on Wall Street yesterday.
Covidien’s Meelia rejoins Haemonetics board as chairman | Personnel Moves
Richard Meelia, the outgoing CEO of Covidien plc (NYSE:COV), is re-joining the board of directors at Haemonetics Corp. (NYSE:HAE) two years after stepping down to focus on Covidien.
Meelia, who plans to retire from Covidien’s corner office July 1 (he’ll stay on as non-executive chairman for the Mansfield, Mass.-based medical products maker), served on Haemonetics’ board from 2005 through 2009.
Haemonetics breaks annual sales record, Q4 profits up five fold | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Haemonetics once again narrows 2011 guidance
Haemonetics Corp. (NYSE:HAE) said for the second straight quarter that it will not meet previous sales estimates for 2011.
The Braintree, Mass.-based blood management firm narrowed its top-line growth estimate to 6 percent to 7 percent, down from the 6 percent to 9 percent (itself a downgrade from the 9 percent to 12 percent growth forecast Haemonetics issued at the start of its fiscal year).
The readjustment came with the announcement of an otherwise strong third quarter for the company.
MassDevice New Year’s Special | Brian Concannon
Change is in the air at Haemonetics as Nutter steps away
Brad Nutter, the turnaround artist who helped pump new life into Haemonetics Corp. (NYSE:HAE) as CEO and later chairman of the board, said he will retire from the company’s board of directors effective November 1, 2010.
The move, announced on Monday in conjunction with the company’s first quarter earnings release, completes the transition to current CEO Brian Concannon, who moved into the corner office in April 2009.
UPDATE: USPTO upholds Haemonetics patent in spat with Fenwal
A federal court put the kaibosh on a lower court’s decision to award $15.7 million to Haemonetics Corp. (NYSE:HAE) in a patent spat with Fenwal Inc.
Haemonetics sued Fenwal in 2005, alleging that the then-Baxter Healthcare (NYSE:BAX) subsidiary infringed a Haemonetics patent for a portable blood-collection device.
Big gains for Haemonetics in fiscal 2010
Haemonetics Corp. (NYSE:HAE) topped expectations for its recently concluded fiscal year, turning in adjusted net income of $74 million on $645 million in revenues during the 12 months ended March 31.
The $2.85-per-share adjusted profit in fiscal 2010 beat most analysts’ forecasts by 2 cents and marked a 16 percent jump from year-ago levels. The Braintree, Mass.-based maker of blood separation tools also said revenues should grow by up to 12 percent next year, with adjusted earnings climbing as much as 14 percent in fiscal 2011.